Cinclus Pharma Holding AB (FRA:J8P) ROCE %: -97.79% (As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €0.96
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB ROCE %?

Cinclus Pharma Holding AB FRA:J8P -1.23% 6 ROCE % is -97.79% as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cinclus Pharma Holding AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -97.79%.

Cinclus Pharma Holding AB  (FRA:J8P) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cinclus Pharma Holding AB ROCE % Related Terms

Cinclus Pharma Holding AB ROCE % Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB ROCE % Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-59.71 -167.11 -574.62 -65.58 -39.20

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.53 -34.76 -34.13 -55.28 -97.79
FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB ROCE % Calculation

Cinclus Pharma Holding AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-16.845/( ( (52.25 - 3.955) + (50.224 - 12.57) )/ 2 )
=-16.845/( (48.295+37.654)/ 2 )
=-16.845/42.9745
=-39.20 %

Cinclus Pharma Holding AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-33.74/( ( (50.224 - 12.57) + (47.5 - 16.15) )/ 2 )
=-33.74/( ( 37.654 + 31.35 )/ 2 )
=-33.74/34.502
=-97.79 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -97.79% mean?
Cinclus Pharma Holding AB (FRA:J8P) has a ROCE % of -97.79% as of Mar. 2026.
Is Cinclus Pharma Holding AB's ROCE % too high?
Cinclus Pharma Holding AB's current ROCE % is -97.79%. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's ROCE % compare to ZTS?
Cinclus Pharma Holding AB's ROCE % of -97.79% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current ROCE % is -97.79%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current ROCE % of -97.79%. The current ROCE % is -97.79%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current ROCE % is -97.79% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price